logo
Takeda’sZasocitinibSignificantlyOutperformsDeucravacitinibinHead-to-HeadPhase3PsoriasisStudy,PromisingtoRedefineOralTreatmentExpectations
===2026/6/12 9:58:16===
; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and o
=*=*=*=*=*=
当前为第12/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页